Skip to main content

Advertisement

SpringerLink
Log in

Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization

  • Basic Science
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

Pericytes, which are recruited to vessels via platelet-derived growth factor (PDGF), are linked to vessel formation and stabilization during pathological corneal neovascularization. In advanced stage, maturated vessels are restricted to anti-VEGF therapy. This study was undertaken to investigate the potential anti-angiogenesis effect of PDGF receptor inhibitor and the therapeutic effect of simultaneously targeting VEGF/PDGF signaling in advanced stage mouse corneal neovascularization.

Method

Corneal neovascularization was induced in wild-type BALB/C mice by removal of the corneal and limbal epithelia. To study the effects of anti-angiogenic inhibitor on new vessel growth prevention, mice were treated with VEGF receptor tyrosin kinase inhibitor II(anti-VEGF/VEGFR group) for 10 days immediately following injury at day 0 (D0). To study the effects of anti-angiogenic inhibitors on vessel regression, mice were treated with VEGF receptor tyrosin kinase inhibitor II or PDGF receptor inhibitor AG 1296 (anti-PDGF/PDGFR group) or both (combined group) for 10 days starting at day 10 (D10) post-injury. Corneas were harvested and immunostained with CD31 for endothelial cells and Ng2 for pericytes. Threshold analysis was used to calculate the area of corneal new vessels. Corneal flatmounts were studied under fluorescence microscope and confocal microscope.

Results

Mice treated with the VEGF receptor tyrosin kinase inhibitor II from D0 showed an inhibition of corneal neovascularization of 15.4% compared with untreated animals (P < 0.01). But the same amount of VEGF receptor tyrosin kinase inhibitor II had no significant anti-angiogenic effect when used at D10 (P > 0.05). Mice treated with either AG1296 or AG1296 plus VEGF receptor tyrosin kinase inhibitor II at D10 showed an inhibition of corneal neovascularization of 12.59% (P < 0.05) and 20.85% (P < 0.01) respectively. Decreased pericyte coverage and vessel density was observed in AG1296 group. Compared to the anti-VEGF/VEGFR group, only the combined therapy group showed a significant anti-angiogenesis effect (P < 0.01).

Conclusion

Inhibition of the PDGF signal pathway results in loss of pericytes and a reduction in vessel density in advanced stage mouse corneal neovascularization. Furthermore, pericyte attenuation caused by blockade PDGF signaling can enhance the anti-angiogenesis efficacy of VEGF receptor inhibitor. Combined treatment against both endothelial cells and pericytes is required for advanced stage corneal new vessels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Epstein RJ, Stulting RD, Hendricks RL, Harris DM (1987) Corneal neovascularization. Pathogenesis and inhibition. Cornea 6(4):250–257

    Article  PubMed  CAS  Google Scholar 

  2. Lee P, Wang CC, Adamis AP (1998) Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 43(3):245–269

    Article  PubMed  CAS  Google Scholar 

  3. Risau W (1997) Mechanisms of angiogenesis. Nature 386:671–674

    Article  PubMed  CAS  Google Scholar 

  4. Nehls V, Denzer K, Drenckhahn D (1992) Pericyte involvement in capillary sprouting during angiogenesis in situ. Cell Tissue Res 270:469–474

    Article  PubMed  CAS  Google Scholar 

  5. Cabebe E, Wakelee H (2007) Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 8(1):15–27

    Article  PubMed  Google Scholar 

  6. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D’Amore PA, Miller JW (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114:66–71

    PubMed  CAS  Google Scholar 

  7. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP (1998) Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 39:18–22

    PubMed  CAS  Google Scholar 

  8. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LE (1996) Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 93:4851–4856

    Article  PubMed  CAS  Google Scholar 

  9. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O’Neill CA, Miller JW (2002) Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120:338–346

    PubMed  CAS  Google Scholar 

  10. Singh N, Higgins E, Amin S, Jani P, Richter E, Patel A, Kaur R, Wang J, Ambati J, Dong Z, Ambati BK (2007) Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization. Cornea 26(1):65–72

    Article  PubMed  Google Scholar 

  11. Singh N, Higgins E, Amin S, Jani P, Richter E, Patel A, Kaur R, Wang J, Ambati J, Dong Z, Ambati BK (2005) Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. Invest Ophthalmol Vis Sci 46(5):1647–1652

    Article  PubMed  Google Scholar 

  12. Benjamin LE, Hemo I, Keshet E (1998) A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125:1591–1598

    PubMed  CAS  Google Scholar 

  13. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159–165

    Article  PubMed  CAS  Google Scholar 

  14. Joussen AM, Poulaki V, Mitsiades N, Stechschulte SU, Kirchhof B, Dartt DA, Fong GH, Rudge J, Wiegand SJ, Yancopoulos GD, Adamis AP (2003) VEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis Sci 44:117–123

    Article  PubMed  Google Scholar 

  15. Proia AD, Chandler DB, Haynes WL, Smith CF, Suvarnamani C, Erkel FH, Klintworth GK (1988) Quantitation of corneal neovascularization using computerized image analysis. Lab Invest 58:473–479

    PubMed  CAS  Google Scholar 

  16. Ebrahem Q, Chaurasia SS, Vasanji A, Qi JH, Klenotic PA, Cutler A, Asosingh K, Erzurum S, Anand-Apte B (2010) Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. Am J Pathol 176(1):496–503

    Article  PubMed  CAS  Google Scholar 

  17. Conners MS, Urbano F, Vafeas C, Stoltz RA, Dunn MW, Schwartzman ML (1997) Alkali burn-induced synthesis of inflammatory eicosanoids in rabbit corneal epithelium. Invest Ophthalmol Vis Sci 38(10):1963–1971

    PubMed  CAS  Google Scholar 

  18. Campos-Mollo E, Pérez-Santonja JJ, Lledó-Riquelme M, Ortega Pastor E, Alió JL (2011) New corneal neovascularization model in rabbits for angiogenesis research. Ophthalmic Res 45(3):135–141

    Article  PubMed  Google Scholar 

  19. Ma DH, Chen JK, Zhang F, Lin KY, Yao JY, Yu JS (2006) Regulation of corneal angiogenesis in limbal stem cell deficiency. Prog Retin Eye Res 25(6):563–590

    Article  PubMed  CAS  Google Scholar 

  20. Alon T, Hemo I, Itin A, Pe’er J, Stone J, Keshet E (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1:1024–1028

    Article  PubMed  CAS  Google Scholar 

  21. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE (1995) VEGF expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 92:905–909

    Article  PubMed  CAS  Google Scholar 

  22. Shibuya M, Claesson-Welsh L (2006) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312:549–560

    Article  PubMed  CAS  Google Scholar 

  23. Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM (2003) Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol 162:1883–193

    Google Scholar 

  24. Helfrich I, Scheffrahn I, Bartling S, Weis J, von Felbert V, Middleton M, Kato M, Ergün S, Schadendorf D (2010) Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 207(3):491–503

    Article  PubMed  CAS  Google Scholar 

  25. Cursiefen C, Hofmann-Rummelt C, Küchle M, Schlötzer-Schrehardt U (2003) Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation. Br J Ophthalmol 87(1):101–106

    Article  PubMed  CAS  Google Scholar 

  26. Hoppenreijs VPT, Pels E, Vrensen GF, Felten PC, Treffers WF (1993) Platelet-derived growth factor: receptor expression in corneas and effects on corneal cells. Invest Ophthalmol Vis Sci 34:637–649

    PubMed  CAS  Google Scholar 

  27. Kim WJ, Mohan RR, Mohan RR, Wilson SE (1999) Effect of PDGF, IL-1alpha, and BMP2/4 on corneal fibroblast chemotaxis: expression of the platelet-derived growth factor system in the cornea. Invest Ophthalmol Vis Sci 40(7):1364–1372

    PubMed  CAS  Google Scholar 

  28. Abramsson A, Lindblom P, Betsholtz C (2003) Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 112(8):1142–1151

    PubMed  CAS  Google Scholar 

  29. Lindblom P, Gerhardt H, Liebner S, Abramsson A, Enge M, Hellstrom M, Backstrom G, Fredriksson S, Landegren U, Nystrom HC, Bergstrom G, Dejana E, Ostman A, Lindahl P, Betsholtz C (2003) Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 17(15):1835–1840

    Article  PubMed  CAS  Google Scholar 

  30. Jain RK, Booth MF (2003) What brings pericytes to tumor vessels? J Clin Invest 112(8):1134–1136

    PubMed  CAS  Google Scholar 

  31. Reinmuth N, Liu W, Jung YD, Ahmad SA, Shaheen RM, Fan F, Bucana CD, McMahon G, Gallick GE, Ellis LM (2001) Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J 15(7):1239–1241

    PubMed  CAS  Google Scholar 

  32. Bergers G, Song S (2005) The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol 7(4):452–464

    Article  PubMed  CAS  Google Scholar 

  33. Hasumi Y, Kłosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C (2007) Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer 121(12):2606–2614

    Article  PubMed  CAS  Google Scholar 

  34. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P (2004) Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18(2):338–340

    PubMed  CAS  Google Scholar 

  35. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Investig 111(9):1287–1295

    PubMed  CAS  Google Scholar 

  36. Uzui H, Lee JD, Shimizu H, Tsutani H, Ueda T (2000) The role of protein–tyrosine phosphorylation and gelatinase production in the migration and proliferation of smooth muscle cells. Atherosclerosis 149(1):51–59

    Article  PubMed  CAS  Google Scholar 

  37. Westermark B, Claesson-Welsh L, Heldin CH (1989) Structural and functional aspects of the receptors for platelet-derived growth factor. Prog Growth Factor Res 1(4):253–266

    Article  PubMed  CAS  Google Scholar 

  38. Bradley DA, Dunn R, Nanus D, Stadler W, Dreicer R, Rosenberg J, Smith DC, Hussain M (2007) Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clin Genitourin Cancer 5(7):460–463

    Article  PubMed  CAS  Google Scholar 

  39. Kim DW, Lu B, Hallahan DE (2004) Receptor tyrosine kinase inhibitors as anti-angiogenic agents. Curr Opin Investig Drugs 5(6):597–604

    PubMed  CAS  Google Scholar 

  40. Pérez-Santonja JJ, Campos-Mollo E, Lledó-Riquelme M, Javaloy J, Alió JL (2010) Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and sunitinib (anti-VEGF and anti-PDGF) in an animal model. Am J Ophthalmol 150:519–528

    Article  PubMed  Google Scholar 

Download references

No financial relationship with the organization that sponsored the research exists. The authors have full control of all primary data, and agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data upon request.

Author information

Authors and Affiliations

  1. Ophthalmology Department, Eye & ENT Hospital of Fudan University, 83 Fenyang Road, Shanghai, 200031, China

    Zhang Chaoran, Lin Zhirong & Xu Gezhi

Authors
  1. Zhang Chaoran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lin Zhirong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xu Gezhi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xu Gezhi.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOC 29 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chaoran, Z., Zhirong, L. & Gezhi, X. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 249, 1493–1501 (2011). https://doi.org/10.1007/s00417-011-1709-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-011-1709-6

Keywords

Search

Navigation